World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board
09. Februar 2017 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications...
PetLife Pharmaceuticals Announces Son of World Famous Veterinarian & Pet Industry Innovator, Geoffrey Broderick, to Join the Company as the New President
03. Februar 2017 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Feb. 03, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications...
PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
10. Januar 2017 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Jan. 10, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
07. Dezember 2016 08:50 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
07. Dezember 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission
06. Dezember 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Dec. 06, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings
01. Dezember 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Dec. 01, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
15. November 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Nov. 15, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline
27. Oktober 2016 10:30 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Hancock, MD - Innovative veterinary health company, PetLife Pharmaceuticals, Inc. (OTC QB: PTLF), announced today a partnership with Lumleian, LLC, a...
PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
24. Oktober 2016 12:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 24, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...